Skip to main content

Table 1 Clinical and laboratory characteristics of ankylosing spondylitis patients, with high and low disease activity and controls

From: High disease activity in ankylosing spondylitis is associated with increased serum sclerostin level and decreased wingless protein-3a signaling but is not linked with greater structural damage

  High disease activity (BASDAI ≥ 4) Low disease activity (BASDAI < 4) Healthy controls
  n = 50 n = 28 n = 23
age in years (SD) 37.8 (11.6)*& 32.0 (6.6) 32.3 (7.5)
disease duration in years (SD) 9.0 (6.7) 7.2 (5.0) NA
BASDAI (SEM) 7.17 (0.24)* 2.79 (0.15) NA
ESR mm/hr (SEM) 34.7 (3.09)*& 21.3 (3.74)& 6.3 (0.79)
CRP mg/l (SEM) 23.4 (3.87)*& 10.7 (2.24) & 0.89 (0.16)
TNF alpha pg/ml (SEM) 2.03 (0.19) & 2.56 (0.74) & 1.77 (0.24)
IL-6 pg/ml (SEM) 6.01 (1.53) & 4.4 (0.66) & 0.80 (0.007)
IL-18 pg/ml (SEM) 446.25 (30.62) 418.0 (28.2) 394.0 (21.8)
Dkk-1 pg/ml (SEM) 818.7 (114.9)* & 1692.7 (122.3) & 1349.3 (82.7)
sclerostin ng/ml (SEM) 0.34 (0.09) & 0.21 (0.12) 0.12 (0.09)
Wnt-3a ng/ml (SEM) 12.6 (2.46)* & 26.3 (2.24) & 16.9 (2.4)
BMP-7 pg/ml (SEM) 5.46 (0.92) 5.67 (0.97) 5.6 (1.09)
MMP-3 ng/ml (SEM) 11.6 (2.46)* & 56.1 (36.7) 13.1 (1.28)
OPG pmol/ml (SEM) 4.8 (0.34) & 4.0 (0.21) 3.9 (1.16)
BALP U/l (SEM) 76.9 (9.15) 57.7 (3.36) 53.4 (8.0)
mSASSS 8 (4-51) 8 (1-22) NA
median (5–95 percentile)
  1. *p < 0,05 vs. low disease activity group.
  2. &p < 0,05 vs. control group.
  3. AS Ankylosing spondylitis, BASDAI Bath ankylosing spondylitis disease activity index; ESR erythrocyte sedimentation rate, CRP C-reactive protein, TNF alpha Tumour necrosis factor alpha, IL-6 interleukin 6, IL-18 Interleukin 18, Dkk-1 Dickkopf-1 protein, Wnt-3a wingless protein-3a, BMP-7 Bone morphogenic protein-7, MMP-3 Matrix metalloproteinase 3, OPG Osteoprotegerin, BALP Bone alkaline phosphatase, mSASSS Modified Stoke’s ankylosing spondylitis spine score, NA Not applicable, SD Standard deviation, SEM Standard error of the mean.